“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande's transition from leading a $4 billion biotech practice at a16z to starting his own, smaller venture firm VZVC, has raised eyebrows in the tech and biotech communities. Pande's assertion that he's not taking on 30 bets a year, as some might expect from a venture firm, suggests a more measured and deliberate approach to investing. This shift towards a more conservative strategy could be a reflection of Pande's experience managing a large fund and his desire to focus on high-conviction investments.

The broader context of Pande's comments on the biotech industry is also noteworthy. He highlights the shift from biology being a "discovery" science to an "engineering" one, which could have significant implications for the development of new treatments and therapies. Additionally, his mention of clinical trials remaining "brutally expensive" underscores a major pain point in the industry. As tech and biotech continue to converge, investors and entrepreneurs will be watching to see how Pande's new firm navigates these challenges.

Looking ahead, it's worth watching how VZVC's AI-native approach to biotech investing plays out. With Pande at the helm, the firm is likely to focus on cutting-edge technologies and innovative startups. As the biotech industry continues to evolve, the intersection of AI, engineering, and biology will be an area to watch, particularly in terms of how it impacts clinical trials and the development of new treatments. Will Pande's smaller, more focused approach yield better returns than his previous large-scale efforts? Only time will tell, but the tech and biotech communities will be keeping a close eye on his progress.

Originally reported by techcrunch.com. TechNews adds analysis for technology readers.